Stealth Reports Positive Results from Ischaemia Reperfusion Injury Study

Safety data from the clinical trial and preliminary results showed that Bendavia appears to be safe and well-tolerated at the dose evaluated, without any serious adverse events reported.

Stealth Peptides has received positive results from a Phase I clinical study to evaluate Bendavia, a novel compound that targets the mitochondria to treat ischaemia reperfusion injury, the tissue damage caused when blood supply returns to the tissue after a period of ischemia.

The study enrolled healthy volunteers, who were given a single dose a of Bendavia administered as an intravenous infusion over an extended period.

Safety data from the clinical trial and preliminary results showed that Bendavia appears to be safe and well-tolerated at the dose evaluated, without any serious adverse events reported. Pharmacokinetic analysis from related clinical studies also